Cooperative Agreement U01CA287852
- The National Institute of Biomedical Imaging and Bioengineering (NIBIB) has awarded a $693,156 Project Grant (CFDA 93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health) to the Dana-Farber Cancer Institute, Inc. (DFCI) to develop artificial intelligence (AI) algorithms for predicting prognosis and optimizing treatment selection for cutaneous squamous cell carcinoma (CSCC), a highly prevalent form of skin cancer. The project aims to train and validate AI...
- Federal Grant Award Summary New York University School of Medicine received a $681,215 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) beginning September 1, 2025 and concluding August 31, 2030. The project aims to develop artificial intelligence (AI)-enabled magnetic resonance (MR) imaging technology to support point-of-care prostate cancer detection at the population level. The research challenges conventional...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded $426,828 to The University of Texas Southwestern Medical Center on July 2, 2026, for an exploratory R21 project developing an artificial intelligence (AI)-based prognostic model for Ewing sarcoma using digital pathology images. The two-year project (completion date June 30, 2028) will leverage the largest Ewing sarcoma digital pathology dataset...
- Federal Grant Award Summary The National Cancer Institute awarded a $371,161 Project Grant to the University of Colorado-Denver under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on September 1, 2025, for a two-year performance period concluding August 31, 2027. The award funds the development of artificial intelligence (AI) algorithms designed to improve cervical cancer screening in low-resource settings. Specifically, the project will create advanced AI risk stratification...
- Federal Grant Award Summary Wake Forest University Health Sciences received a $402,728 Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded July 16, 2025, with completion targeted for June 30, 2027. The award supports development of interpretable deep learning models for multi-modality imaging-based gastric cancer prognosis. The project addresses the critical clinical need to improve prognostic accuracy and...
- Federal Project Grant Award Summary Case Western Reserve University received a $147,486 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), awarded December 1, 2025, with completion targeted for May 31, 2027. The award supports the development of a pathologically interpretable computational imaging predictor to identify rectal cancer patients exhibiting complete response (CR) to total neoadjuvant therapy (TNT) who are candidates for...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded $140,400 to Sloan-Kettering Institute for Cancer Research under the Cancer Research Manpower program (CFDA 93.398) to develop artificial intelligence (AI)-based methods that integrate genomic and histopathologic data to advance precision cancer medicine. This Project Grant, awarded July 17, 2026, and scheduled for completion by June 30, 2028, funds research focused on creating multimodal, interpretable AI models that combine...
- Federal Project Grant Award Summary New York University School of Medicine received a $700,171 Project Grant award dated July 16, 2026, from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to advance clinically translatable deep learning (DL) models for prostate cancer detection on magnetic resonance imaging (MRI). The project, with a completion date of June 30, 2031, addresses critical gaps in prostate MRI interpretation by developing robust...
- Grant Award Summary The National Cancer Institute (NCI) awarded $409,141 to the University of California, Davis on June 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop perfusion CT (computed tomography) imaging as an alternative diagnostic tool for liver radioembolization treatment planning. The research project, which runs through May 31, 2028, seeks to replace the current complex, time-intensive workup procedure for selective internal radiation...
- Federal Grant Award Summary Duke University received a $109,767 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398), effective July 1, 2026 through June 30, 2038. This K99/R00 award supports the development of novel artificial intelligence (AI) frameworks designed to analyze single-cell and spatial transcriptomic data for colorectal cancer research. During the K99 mentored phase, the project will develop and validate SPACT (Spatial Pathway...
LEVERAGING ARTIFICIAL INTELLIGENCE/MACHINE LEARNING-BASED TECHNOLOGY TO OVERCOME SPECIALIZED TRAINING AND TECHNOLOGY BARRIERS FOR THE DIAGNOSIS AND PROGNOSTICATION OF COLORECTAL CANCER IN AFRICA - SUMMARY/ABSTRACT COLORECTAL CANCER (CRC) IS THE THIRD MOST COMMONLY DIAGNOSED CANCER AND THE SECOND LEADING CAUSE OF CANCER RELATED DEATHS WORLDWIDE. RATES IN AFRICA ARE ON THE RISE, BUT ESSENTIAL HISTOPATHOLOGY SERVICES CRITICAL FOR CANCER CARE ARE SCARCE. TO ADDRESS THIS BARRIER, WE DEVELOPED AN ARTIFICIAL INTELLIGENCE (AI)/MACHINE LEARNING (ML)-BASED COMPUTATIONAL PIPELINE (SIVQ/VIPR) THAT PERFORMS AUTOMATED PIXEL-LEVEL IMAGE SEGMENTATION AND CLASSIFICATION FROM DIGITAL IMAGES OF ROUTINELY COLLECTED HEMATOXYLIN AND EOSIN (H & E)-STAINED SLIDES. SIVQ/VIPR IS HIGHLY PRECISE, REPRODUCIBLE, AND OUTPERFORMS SUBJECT MATTER EXPERTS. ONCE HISTOLOGICALLY DISTINCT REGIONS ARE IDENTIFIED, IMAGE ANALYSIS ALGORITHMS CAN THEN IDENTIFY INDIVIDUAL REGIONS AND AGGREGATE THEM TO PREDICT DIAGNOSTIC AND PROGNOSTIC FEATURES IN CONJUNCTION WITH CLINICAL OUTCOMES TO GUIDE TREATMENT. OUR OVERALL APPROACH IS TO LEVERAGE OUR VALIDATED SIVQ/VIPR COMPUTATIONAL PIPELINE TO DEVELOP AND VALIDATE AN AI-BASED DIAGNOSTIC DECISION SUPPORT (AI-DDS) TOOL FOR CRC DIAGNOSIS AND PROGNOSIS IN AN EXISTING KENYAN COHORT. TO CARRY OUT THIS WORK, THE AGA KHAN UNIVERSITY (AKU)- EAST AFRICA AND THE UNIVERSITY OF MICHIGAN HAVE PARTNERED WITH TENWEK HOSPITAL, A NON-ACADEMIC COMMUNITY-BASED PUBLIC HOSPITAL IN RURAL BOMET, KENYA, TO DEVELOP A UNIQUE COLLABORATION OF ONCOLOGISTS, PATHOLOGISTS, SURGEONS, STATISTICIANS, AND INFORMATICIANS, MAKING US UNIQUELY SUITED TO DEVELOP POPULATION-RELEVANT, AFFORDABLE, AND SCALABLE DATA SCIENCE SOLUTIONS IN KENYA - ALL PRIORITIES OF THE DS-I AFRICA PROGRAM. WE WILL: AIM 1. ADAPT AND VALIDATE AN EXISTING ML-BASED DIAGNOSTIC ALGORITHM FOR CRC USING DIGITAL FIELDS OF VIEW FROM H & E-STAINED SLIDES IN A RETROSPECTIVE COHORT OF N=675 CRC CASES FROM THE AKU AND TENWEK HOSPITALS. WE WILL APPLY THE CRC-TRAINED SIVQ/VIPR COMPUTATIONAL PIPELINE FOR SEGMENTATION AND CLASSIFICATION FOR CRC FEATURES, FOLLOWED BY A CONFIRMATORY CLASSIFIER STEP TO ACHIEVE A CASE LEVEL, BINARY RESULT OF A CANCER/NO-CANCER (I.E., DIAGNOSIS). AIM 2. DEVELOP AND REFINE AN UNSUPERVISED ML METHOD TO IDENTIFY HISTOPATHOLOGY IMAGE-DERIVED MEASUREMENTS ASSOCIATED WITH CRC PROGNOSIS. WE WILL USE COMPUTER/MACHINE VISION APPROACHES TO IDENTIFY IMAGE FEATURES (E.G., CELLULAR MORPHOLOGY) DISCRIMINATIVE OF CRC PROGNOSIS AND BIOLOGICAL POTENTIAL FOR DISEASE AGGRESSIVENESS. COMBINED USE OF AI-BASED MORPHOLOGICAL SIGNATURES OF AGGRESSIVE DISEASE (E.G., HIGH-GRADE TUMOR ARCHITECTURE) WILL BE COMPILED WITH OTHER CLINICALLY RELEVANT FEATURES TOWARDS THE GOAL OF GENERATING A MULTI-AXIAL MULTIPLEXED AI-DDS TOOL THAT CAN MAXIMALLY INFORM OF THE BIOLOGICAL AND METASTATIC POTENTIAL OF EACH CRC CASE. THIS PROJECT WILL LAY THE GROUNDWORK FOR AN AI-DDS TOOL FOR CLINICIANS (E.G., PATHOLOGISTS, ONCOLOGISTS) THAT FACILITATES PROMPT AND ACCURATE DIAGNOSIS, PROGNOSIS, AND RISK STRATIFICATION FOR CRC CARE IN AFRICA. BECAUSE THIS APPROACH LEVERAGES OPEN-SOURCE SOFTWARE AND CAN BE DEPLOYED AS A TURN-KEY SYSTEM INTENDED FOR WEB-BASED CLOUD DEPLOYMENT, IT IS WELL-SUITED FOR CAPACITY BUILDING, INTEGRATING INTO EDUCATIONAL PROGRAMS, AND EXPANDING TO OTHER EMERGENT OR PREVALENT CANCERS (I.E., BREAST, CERVICAL, PROSTATE) AS PART OF THE DS-I AFRICA CONSORTIUM.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 3/18/26 | ||
| Not listed | $250.0k | 9/18/25 | ||
| Not listed | $250.0k | 9/18/25 | ||
| Not listed | $12.5k | 8/27/24 | ||
| Not listed | $237.5k | 8/16/24 |